Statistik Asas
| CIK | 1604477 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to SQZ Biotechnologies Co
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| February 13, 2024 |
EX-99.1 2 tm245791d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 IDENTIFICATION OF THE SUBSIDIARIES WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. American International Group, Inc. — Subsidiary Information Corebridge DECO II, LLC American Home Assurance Company Lexington Insurance Company National Union Fire Insurance Company of Pittsburgh, Pa. |
|
| February 13, 2024 |
SQZ / SQZ Biotechnologies Co / AMERICAN INTERNATIONAL GROUP, INC. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240. |
|
| February 9, 2024 |
SQZ / SQZ Biotechnologies Co / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A 1 d745311dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 3) SQZ Biotechnologies Company (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 78472W104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| January 23, 2024 |
DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 12, 2024 |
PREM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 12, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Schedule 14A (Form Type) SQZ Biotechnologies Company (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid $11,800,000. |
|
| January 4, 2024 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39662 SQZ BIOTECHNOLOGIES COMPANY (Exact name of registrant as sp |
|
| December 22, 2023 |
Exhibit 2.1 Execution Version ASSET PURCHASE AGREEMENT between STEMCELL TECHNOLOGIES CANADA ACQUISITIONS INC. and SQZ BIOTECHNOLOGIES COMPANY Dated December 21, 2023 SUMMARY OF CONTENTS Article 1 Sale and Transfer of Assets; Purchase Price; Closing 1 Article 2 Closing 3 Article 3 Representations and Warranties of Seller 5 Article 4 Representations and Warranties of Purchaser 14 Article 5 Covenants |
|
| December 22, 2023 |
EX-10.1 Exhibit 10.1 * Certain identified information has been excluded from this exhibit (indicated by “[***]”) pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type that the registrant treats as private or confidential. Massachusetts Institute of Technology and SQZ Biotechnologies Company Second Amendment to Amended and Restated Exclusive Patent Licens |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 30, 2023 |
As filed with the Securities and Exchange Commission on November 30, 2023 As filed with the Securities and Exchange Commission on November 30, 2023 Registration No. |
|
| November 30, 2023 |
As filed with the Securities and Exchange Commission on November 30, 2023 As filed with the Securities and Exchange Commission on November 30, 2023 Registration No. |
|
| November 8, 2023 |
SQZ Biotechnologies Company Non-Employee Director Compensation Program EXHIBIT 10.1 SQZ Biotechnologies Company Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of SQZ Biotechnologies Company (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be made |
|
| November 8, 2023 |
EXHIBIT 10.2 Transition Agreement This Transition Agreement (the “Agreement”) is made as of October 3, 2023 (the “Notice Date”), by and between SQZ Biotechnologies Company (the “Company”) and Howard Bernstein, M.D., Ph.D. (the “Executive”) (collectively referred to as the “parties” or individually referred to as a “party”). Capitalized terms used but not defined in this Agreement shall have the me |
|
| November 8, 2023 |
EXHIBIT 10.4 Transition Agreement This Transition Agreement (the “Agreement”) is made as of October 3, 2023 (the “Notice Date”), by and between SQZ Biotechnologies Company (the “Company”) and Lawrence Knopf (the “Executive”) (collectively referred to as the “parties” or individually referred to as a “party”). Capitalized terms used but not defined in this Agreement shall have the meanings set fort |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39662 SQZ BIOTECHNOLOGIES COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 46-2431115 (State or other jurisdiction of incorporation or organization) (I. |
|
| November 8, 2023 |
EXHIBIT 10.5 Transition Agreement This Transition Agreement (the “Agreement”) is made as of October 3, 2023 (the “Notice Date”), by and between SQZ Biotechnologies Company (the “Company”) and Marshelle Smith Warren (the “Executive”) (collectively referred to as the “parties” or individually referred to as a “party”). Capitalized terms used but not defined in this Agreement shall have the meanings |
|
| November 8, 2023 |
EXHIBIT 10.3 Transition Agreement This Transition Agreement (the “Agreement”) is made as of October 3, 2023 (the “Notice Date”), by and between SQZ Biotechnologies Company (the “Company”) and Richard Capasso (the “Executive”) (collectively referred to as the “parties” or individually referred to as a “party”). Capitalized terms used but not defined in this Agreement shall have the meanings set for |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 15, 2023 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39662 SQZ BIOTECHNOLOGIES COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 46-2431115 (State or other jurisdiction of incorporation or organization) (I. |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 19, 2023 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange ("NYSE" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the entire class of common stock (the "Securities") of SQZ Biotechnologies Company (the "Company") from listing and registration on the Exchange on July 31, 2023, pursuant to the provisions of Rule 12d2-2(b) because, in the opinion of the Exchange, the Securities are no longer suitable for continued listing and trading on the NYSE. |
|
| July 7, 2023 |
Empower Cells to Change Lives Exhibit 10.1 To: EMPLOYEE From: David First July 10, 2023 Dear EMPLOYEE, We are excited to share that the Board of Directors has approved the payment to you of a retention recognition bonus, subject to the terms of this agreement. By July 14, 2023, you will receive a payment in the amount of: $TOTAL BONUS PAYOUT, less applicable taxes, provided you sign and return thi |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2023 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39662 SQZ BIOTECHNOLOGIES COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 46-2431115 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 10, 2023 |
Amended Non-Employee Director Compensation Program Exhibit 10.1 SQZ Biotechnologies Company Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of SQZ Biotechnologies Company (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be made |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2023 SQZ BIOTECHNOLOGIES COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39662 46-2431115 (State or other jurisdiction of (Commission (IRS Employe |
|
| March 22, 2023 |
Separation Agreement between the Registrant and Armon Sharei, dated November 30, 2022 Exhibit 10.15 Separation Agreement and Release This Separation Agreement and Release (“Agreement”) is made by and between Armon Sharei, Ph.D. (“Executive”) and SQZ Biotechnologies Company (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Employment A |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39662 SQZ BIOTECHNOL |
|
| March 22, 2023 |
Separation Agreement between the Registrant and Micah Zajic. dated November 28, 202 Exhibit 10.16 November 28, 2022 Via Email - Personal and Confidential Dear Micah: This letter (the “Agreement”) summarizes the terms of your separation from employment with SQZ Biotechnologies Company (“SQZ”or the “Company”) and establishes an amicable arrangement under which you release the Company from any claims, and, in return, you receive separation pay. 1. Employment Status; Final Payments; |
|
| March 22, 2023 |
Employment Agreement between the Registrant and Howard Bernstein, Ph.D., dated November 28, 2022 Exhibit 10.17 Employment Agreement This Employment Agreement (this “Agreement”), dated as of November 28, 2022, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the “Company”), and Howard Bernstein, M.D.,Ph.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become eff |
|
| March 22, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF SQZ BIOTECHNOLOGIES COMPANY Legal Name of Subsidiary Jurisdiction of Organization SQZ Biotechnologies Security Corporation Massachusetts SQZ Biotech HK Limited Hong Kong SQZ Biotech (Shanghai) Co. Limited China |
|
| February 14, 2023 |
SC 13G/A 1 sqzbio13ga1-123122.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* SQZ Biotechnologies Company (Name of Issuer) Common Stock, par value $0.001 per share (Title |
|
| February 14, 2023 |
SQZ / SQZ Biotechnologies Co / NanoDimension II Management Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SQZ biotechnologies company (Name of Issuer) Common Stock (Title of Class of Securities) 78472W 10 4 (CUSIP Number) DECEMBER 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 14, 2023 |
SQZ / SQZ Biotechnologies Co / AMERICAN INTERNATIONAL GROUP, INC. - SC 13G/A Passive Investment SC 13G/A 1 tm236032d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* SQZ Biotechnologies Company (Name of Issuer) Common Stock, Par Value $0.01 per Share (Title of Class of Securities) 7 |
|
| February 14, 2023 |
EX-99.1 2 tm236032d2ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 IDENTIFICATION OF THE SUBSIDIARIES WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. American International Group, Inc. — Subsidiary Information AIG DECO Fund II, LP American Home Assurance Company Lexington Insurance Company National Union Fire Insurance Company of Pittsburgh, Pa. |
|
| February 13, 2023 |
SQZ / SQZ Biotechnologies Co / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) SQZ Biotechnologies Company (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 78472W104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| January 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 18, 2023 |
Empower Cells to Change Lives® EXHIBIT 99.1 SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange WATERTOWN, Mass., January 18, 2023 – SQZ Biotechnologies (NYSE: SQZ) today announced that on January 18, 2023, it received notice from the New York Stock Exchange (NYSE) indicating that the Company is not in compliance with Section 802.01C of the NY |
|
| December 6, 2022 |
Empower Cells to Change Lives® Exhibit 99.1 SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress • Designation Represents Potential to Bring Important New Therapy to Patients Earlier • Stable Disease Observed in |
|
| December 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 06, 2022 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 30, 2022 |
Exhibit 99.1 SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer Strategic Reprioritization of Portfolio: Focus on Advancing Second-Generation Cell Therapy Program, Enhanced Antigen Presenting Cells Howard Bernstein, MD, PhD, Former Chief Scientific Officer, Appointed as Interim Chief Executi |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39662 SQZ BIOTECHNOLOGIES COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 46-2431115 (State or other jurisdiction of incorporation or organization) (I. |
|
| November 9, 2022 |
Exhibit 10.1 September 2, 2022 Via Email - Personal and Confidential Dear Howard: This letter (the ?Agreement?) summarizes the terms of your separation from employment with SQZ Biotechnologies Company (?SQZ? or the ?Company?) and establishes an amicable arrangement under which you release the Company from any claims, and, in return, you receive severance pay. 1. Employment Status; Final Payments; |
|
| November 9, 2022 |
Exhibit 10.2 TRANSITION CONSULTING AGREEMENT This Consulting Agreement (this "Agreement") dated as of November 1, 2022 (the ?Effective Date?), is made by and between SQZ Biotechnologies Company, a Delaware corporation (the "Company"), and Howard Bernstein (the "Consultant"). The Company desires to engage the Consultant to perform consulting services on behalf of the Company and the Consultant desi |
|
| September 6, 2022 |
SQZ Biotechnologies Announces Leadership Transition Chief Scientific Officer, Howard Bernstein, M. |
|
| September 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 4, 2022 |
Exhibit 10.1 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of May 25, 2022, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the ?Company?), and Marshelle Smith Warren (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?), and will become effective on Ju |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39662 SQZ BIOTECHNOLOGIES COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 46-2431115 (State or other jurisdiction of incorporation or organization) (I. |
|
| July 11, 2022 |
Exhibit 99.1 SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer Experienced Biotech Leader and Capital Markets Professional Elevated to Chief Financial Officer from Chief Business Officer Role Appointment Effective July 11, 2022 WATERTOWN, Mass., July 11, 2022 ? SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic area |
|
| July 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 07, 2022 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 11, 2022 |
Employment Agreement between SQZ Biotechnologies Company and Micah Zajic, dated July 7, 2022. Exhibit 10.1 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of July 7, 2022, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the ?Company?), and Micah Zajic (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?), and will become effective as of July 11, 2 |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 31, 2022 |
Empowering Cells to Change Lives Exhibit 99.1 SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D. as Chief Medical Officer Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease Appointment Effective June 1st, 2022 WATERTOWN, Mass., May 31, 2022 ? SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the |
|
| May 31, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 19, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 19, 2022 |
SQZ Biotechnologies Company R&D Event Presentation Dated May 19, 2022. |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39662 SQZ BIOTECHNOLOGIES COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 46-2431115 (State or other jurisdiction of incorporation or organization) (I. |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2022 |
DEFA14A 1 sqz-2022proxynotice.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: |
|
| March 16, 2022 |
Amended Non-Employee Director Compensation Program Exhibit 10.3 SQZ Biotechnologies Company Non-Employee Director Compensation Program Non-employee members of the board of directors (the ?Board?) of SQZ Biotechnologies Company (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Program shall be paid or be made |
|
| March 16, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF SQZ BIOTECHNOLOGIES COMPANY Legal Name of Subsidiary Jurisdiction of Organization SQZ Biotechnologies Security Corporation Massachusetts SQZ Biotech HK Limited Hong Kong |
|
| March 16, 2022 |
Separation Agreement between the Registrant and Teri Loxam, dated November 3, 2021 Exhibit 10.18 November 3, 2021 Via Email - Personal and Confidential Dear Teri, This letter (the ?Agreement?) summarizes the terms of your separation from employment with SQZ Biotechnologies Company (?SQZ? or the ?Company?) and establishes an amicable arrangement under which you release the Company from any claims, and, in return, you receive severance pay. 1. Employment Status; Final Payments; Be |
|
| March 16, 2022 |
Employment Agreement between the Registrant and David First, dated October 29, 2020 Exhibit 10.11 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of October 29, 2020, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the ?Company?), and David First (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?), and will become effective, if at all, |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39662 SQZ BIOTECHNOL |
|
| March 16, 2022 |
Employment Agreement between the Registrant and Howard Bernstein, dated October 29, 2020 Exhibit 10.10 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of October 29, 2020, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the ?Company?), and Howard Bernstein, M.D., Ph.D. (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?), and will become eff |
|
| March 16, 2022 |
Transition Consulting Agreement between the Registrant and Teri Loxam, dated November 11, 2021 Exhibit 10.19 TRANSITION CONSULTING AGREEMENT This Consulting Agreement (this "Agreement") dated as of November 11, 2021, the ?Effective Date?), is made by and between SQZ Biotechnologies Company, a Delaware corporation (the "Company"), and Teri Loxam (the "Consultant"). The Company desires to engage the Consultant to perform consulting services on behalf of the Company and the Consultant desires |
|
| February 14, 2022 |
EXHIBIT 99.1 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. American International Group, Inc. ? Subsidiary Information SAFG Retirement Services, Inc.: A parent holding company or control person in accordance with ? 240.13d-1(b)(1)(ii)(G) Category Symbol: HC SAFG Capital LLC: A parent holding company or control perso |
|
| February 14, 2022 |
SQZ / SQZ Biotechnologies Co / AMERICAN INTERNATIONAL GROUP, INC. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240. |
|
| February 14, 2022 |
SQZ / SQZ Biotechnologies Co / Temasek Holdings (Private) Ltd - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 )* SQZ Biotechnologies Company (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class o |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 1)* SQZ Biotechnologies Company (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 78472W104 (CUSIP Number) December 31, 2021 (D |
|
| February 14, 2022 |
EXHIBIT 99.2 AGREEMENT OF JOINT FILING In accordance with Rule 13d-1(k), promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing on behalf of each of them of a Statement on Schedule 13G, and any amendments thereto, with respect to the Common Stock of Macy?s, Inc. and that this Agreement may be included as an Exhibit to such filin |
|
| February 11, 2022 |
SQZ / SQZ Biotechnologies Co / Polaris Management Co. VII, L.L.C. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) SQZ BIOTECHNOLOGIES COMPANY (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 78472W104 (CUSIP Number) Lauren Crockett Polaris Partners One Marina Park Drive, 10th Floor Boston, MA 02210 (781) 290-0770 (Name, Address and Telephone |
|
| February 10, 2022 |
SQZ / SQZ Biotechnologies Co / NanoDimension II Management Ltd - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SQZ biotechnologies company (Name of Issuer) Common Stock (Title of Class of Securities) 78472W 10 4 (CUSIP Number) DECEMBER 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2022 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 24, 2022 |
Empowering Cells to Change Lives Exhibit 99.1 SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors SQZ® Enhanced APCs (eAPCs) Build on Promising Initial SQZ® APC Monotherapy Clinical Data by Broadening the Addressable Patient Population and Incorporating Enhanced |
|
| December 9, 2021 |
Preliminary results of a first-in-human, dose-escalation study of a cell-based vaccine in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors SQZ-PBMC-HPV-101: Jong Chul Park, Joaquina Baranda, Monica Mita, Wade T Iams, Michael S Gordon, Matthew Taylor, Neesha Dhani, Scott Loughhead, Rui Ru Ji, Ricardo F Zwirtes, Martin Kornacker, Oliver Rosen, Howard Bernstein, |
|
| December 9, 2021 |
SQZ-PBMC-HPV-101 Clinical Program Updates at ESMO Immuno-Oncology Congress 2021 Conference Call and Webcast December 9th, 2021 Forward Looking Statements and Legal Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| December 9, 2021 |
Empowering Cells to Change Lives Exhibit 99.1 SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient Patient?s Clinical, Radiographic and Histologic Results Support Potential Impact of SQZ Investigational Therapeutic ? Patient Demonstrated Symptomatic Improvement ? Radiographic Respo |
|
| December 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 09, 2021 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 2, 2021 |
Empowering Cells to Change Lives Exhibit 99.1 SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose Interim SQZ-PBMC-HPV Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and that Therapy was Generally Well Tolerated Oral Presentation at ESMO Immuno-Oncolo |
|
| December 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 02, 2021 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2021 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of I |
|
| November 16, 2021 |
CORRESP 1 filename1.htm November 16, 2021 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Michael Davis Celeste Murphy Re: SQZ Biotechnologies Company Registration Statement on Form S-3 Filed November 12, 2021 Registration No. 333-260980 Ladies and Gentlemen: In acco |
|
| November 12, 2021 |
As filed with the Securities and Exchange Commission on November 10, 2021 S-3 1 d251471ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on November 10, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SQZ BIOTECHNOLOGIES COMPANY (Exact name of registrant as specified in its charter) Delaware 46-2431115 (State or other juris |
|
| November 12, 2021 |
Exhibit 4.3 SQZ BIOTECHNOLOGIES COMPANY INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Estab |
|
| November 12, 2021 |
EX-1.2 2 d251471dex12.htm EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM November 10, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: SQZ Biotechnologies Company, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “A |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39662 SQZ BIOTECHNOLOGIES COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 46-2431115 (State or other jurisdiction of incorporation or organization) (I. |
|
| November 10, 2021 |
Separation Agreement between Oliver Rosen and SQZ Biotechnologies Company, dated September 2, 2021 l Confidential Exhibit 10.1 September 2, 2021 Via Email - Personal and Confidential Dear Oliver, This letter (the ?Agreement?) summarizes the terms of your separation from employment with SQZ Biotechnologies Company (?SQZ? or the ?Company?) and establishes an amicable arrangement under which you release the Company from any claims, and, in return, you receive severance pay. 1. Employment Status; F |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2021 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 26, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 26, 2021 |
Exhibit 99.1 Empowering Cells to Change Lives SQZ Biotechnologies Announces Independent DSMB Recommendation to Advance Lead Cell Therapy Candidate into Combination with Checkpoint Inhibitors High Dose Monotherapy Cohort Clinical Data from the SQZ-PBMC-HPV-101 Trial Accepted for Oral Presentation at ESMO IO in December Cohorts in Combination with anti-PD-(L)1 and anti-CTLA-4 Open for Enrollment Com |
|
| September 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 SQZ BIOTECHNOLOGIES COMPANY (Exact name of Registrant as Specified in Its Charter) Delaware 001-39662 46-2431115 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 13, 2021 |
EX-99.2 3 d149445dex992.htm EX-99.2 Exhibit 99.2 Empower Cells to Change Lives® September 2021 Forward Looking Statements and Legal Disclaimers This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward‐lo |
|
| September 13, 2021 |
Exhibit 99.1 SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform IND filing for Celiac Disease Anticipated in Third Quarter 2022 Clinical Translation Supported by Existing Red Blood Cell-Based Manufacturing Capabilities and Preclinical Models Demonstrating Treg Mediated Tolerance WATERTOWN, Mass., September 13, 2021 ? SQZ Biotechnologies |
|
| September 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 31, 2021 SQZ BIOTECHNOLOGIES COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39662 46-2431115 (State or other jurisdiction of incorporation) (Commis |
|
| August 9, 2021 |
SQZ / SQZ Biotechnologies Co / 683 Capital Management, LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* SQZ Biotechnologies Company (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 78472W104 (CUSIP Number) July 29, 2021 (Date o |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39662 SQZ BIOTECHNOLOGIES COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 46-2431115 (State or other jurisdiction of incorporation or organization) (I. |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2021 SQZ BIOTECHNOLOGIES COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39662 46-2431115 (State or other jurisdiction of inco |
|
| July 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2021 SQZ BIOTECHNOLOGIES COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39662 46-2431115 (State or other jurisdiction of incorporation) (Commissi |
|
| July 1, 2021 |
EX-99.1 2 sqz-ex99114.htm EX-99.1 Exhibit 99.1 SQZ Biotechnologies Strengthens Board with Global Commercial and Clinical Development Experience Bernard Coulie, M.D., Ph.D. and Patrick Vink, M.D. Join Board of Directors WATERTOWN, Mass., July 1, 2021 – SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the appoi |
|
| June 17, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2021 SQZ BIOTECHNOLOGIES COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39662 46-2431115 (State or other jurisdiction of incorporation) (Commissi |
|
| June 4, 2021 |
June 2021 Exhibit 99.2 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including statements relating to our development of our product candidates, the promise and potential |
|
| June 4, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2021 SQZ BIOTECHNOLOGIES COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39662 46-2431115 (State or other jurisdiction of incorporation or organiza |
|
| June 4, 2021 |
EX-99.1 2 sqz-ex99127.htm EX-99.1 Exhibit 99.1 Empowering Cells to Change Lives SQZ Biotechnologies Initial First-In-Human Data Demonstrates Investigational Cell Therapy is Safe and Can Stimulate Immune Responses in Certain Patients with Advanced or Metastatic HPV16+ Tumors Doses of Autologous Cell Therapy Manufactured in Under 24 Hours and Available to Patients in Approximately One Week Clinical |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39662 SQZ BIOTECHNOLOGIES COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 46-2431115 (State or other jurisdiction of incorporation or organization) (I. |
|
| April 26, 2021 |
DEFA14A 1 sqz-defa14a20210426.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39662 SQZ BIOTECHNOL |
|
| March 18, 2021 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED General The following description summarizes some of the terms of our restated certificate of incorporation and restated bylaws, the investors? rights agreement and of the General Corporation Law of the State of Delaware. Because it is only a summary, it does |
|
| February 25, 2021 |
8-K 1 sqz-8k20210223.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2021 SQZ BIOTECHNOLOGIES COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39662 46-2431115 (State or other jurisdi |
|
| February 19, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 SQZ BIOTECHNOLOGIES COMPANY (Name of Issuer) COMMON STOCK (Title of Class of Securities) 78472W 10 4 (CUSIP Number) DECEMBER 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 16, 2021 |
EXHIBIT 99.2 AGREEMENT OF JOINT FILING In accordance with Rule 13d-1(k), promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing on behalf of each of them of a Statement on Schedule 13G, and any amendments thereto, with respect to the Common Stock of Macy’s, Inc. and that this Agreement may be included as an Exhibit to such filin |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) SQZ Biotechnologies Company (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 78472W104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 16, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240. |
|
| February 16, 2021 |
EX-99.1 2 tm216212d4ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. American International Group, Inc. — Subsidiary Information AIG Capital Corporation: A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G) Category Symbol: HC AIG Fund GP Holdings, |
|
| February 16, 2021 |
EX-99.1 2 d117194dex991.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the common stock, $0.001 par value per share, of SQZ Biotechnologies Company, dated as of February 12, 2021, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the p |
|
| February 12, 2021 |
424B4 1 d101785d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-252889 PROSPECTUS 3,000,000 Shares Common Stock We are offering 3,000,000 shares of common stock. Our common stock is listed on the New York Stock Exchange, or NYSE, under the symbol “SQZ.” The last reported sale price of our common stock on the NYSE on February 11, 2021 was $22.01 per share. We |
|
| February 9, 2021 |
February 9, 2021 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| February 9, 2021 |
Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2021 SQZ BIOTECHNOLOGIES COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39662 46-2431115 (State or other jurisdiction of incorporation or |
|
| February 9, 2021 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on February 9, 2021 Registration No. |
|
| February 9, 2021 |
Form of Underwriting Agreement EX-1.1 2 d101785dex11.htm EX-1.1 Exhibit 1.1 [●] SQZ Biotechnologies Company UNDERWRITING AGREEMENT [●], 2021 BOFA SECURITIES, INC. EVERCORE GROUP L.L.C. STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 c/o EVERCORE GROUP L.L.C. 55 East 52nd Street New York, New York 10055 c/o STIFEL, NICOLAUS |
|
| February 9, 2021 |
CORRESP 1 filename1.htm February 9, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: SQZ Biotechnologies Company Registration Statement on Form S-1 Registration No. 333-252889 Acceleration Request Requested Date: February 11, 2021 Requested Time: 4:00 PM, Eastern Time Ladies and Gentlemen: In accordance with Rule 4 |
|
| February 9, 2021 |
Employment Agreement between the Registrant and Lawrence Knopf, dated October 29, 2020 Exhibit 10.15 Employment Agreement This Employment Agreement (this “Agreement”), dated as of October 29, 2020, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the “Company”), and Lawrence Knopf (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at a |
|
| February 9, 2021 |
Employment Agreement between the Registrant and Micah Zajic, dated October 29, 2020 EX-10.16 6 d101785dex1016.htm EX-10.16 Exhibit 10.16 Employment Agreement This Employment Agreement (this “Agreement”), dated as of October 29, 2020, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the “Company”), and Micah Zajic (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”) |
|
| February 9, 2021 |
Amended and Restated Investors’ Rights Agreement, dated as of December 19, 2019, as amended EX-4.1 3 d101785dex41.htm EX-4.1 Exhibit 4.1 THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of December 19, 2019, by and among SQZ Biotechnologies Company, a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as |
|
| February 9, 2021 |
Letter of Katz, Nannis + Solomon, P.C., Independent Public Accountants Exhibit 16.1 February 9, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made SQZ Biotechnologies Company pursuant to Item 304(a)(1) of Regulation S-K (copy attached), which we understand will be filed with the Securities and Exchange Commission as part of the Registration Statement on Form S-1 of SQZ Biotechnologies Compan |
|
| February 1, 2021 |
Table of Contents CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C.F.R. SECTION 200.83 As confidentially submitted with the Securities and Exchange Commission on January 29, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SQZ BIOTECHNOLOGIES COMPANY (Exact name of registrant as spec |
|
| January 29, 2021 |
DRSLTR 1 filename1.htm 200 Clarendon Street Boston, Massachusetts 02116 Tel: +1.617.948.6000 Fax: +1.617.948.6001 www.lw.com FIRM / AFFILIATE OFFICES January 29, 2021 VIA EDGAR AND HAND DELIVERY Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Beijing Boston Brussels Century City Chicago Dubai Düsseldorf Frankfurt Hamburg Hong Kong H |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39662 SQZ BIOTECHNOLOGIES COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 46-2431115 (State or other jurisdiction of incorporation or organization) (I. |
|
| November 13, 2020 |
EX-99.8 3 d88276dex998.htm EX-99.8 Exhibit 8 POWER OF ATTORNEY The undersigned (the “Reporting Person”) hereby constitutes and appoints Lauren Crockett, signing singly, with full power of substitution, as the Reporting Person’s true and lawful attorney in fact to: (1) prepare, execute in the Reporting Person’s name and on the Reporting Person’s behalf, and submit to the U.S. Securities and Exchang |
|
| November 13, 2020 |
SQZ / SQZ Biotechnologies Company / Polaris Management Co. VII, L.L.C. - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) SQZ BIOTECHNOLOGIES COMPANY (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 78472W104 (CUSIP Number) Lauren Crockett Polaris Partners One Marina Park Drive, 10th Floor Boston, MA 02210 (781) 290-0770 (Name, Address and Tel |
|
| November 13, 2020 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.1 2 d88276dex991.htm EX-99.1 Exhibit 1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule and all amendments th |
|
| November 13, 2020 |
SQZ / SQZ Biotechnologies Company / Temasek Holdings (Private) Ltd - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SQZ Biotechnologies Company (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 78472W 104 (CUSIP Number) November 3, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| November 13, 2020 |
EX-99.1 2 d934175dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the common stock, $0.001 par value per share, of SQZ Biotechnologies Company, dated as of November 13, 2020, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the pro |
|
| November 13, 2020 |
SQZ / SQZ Biotechnologies Company / Invus Public Equities, L.P. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) SQZ Biotechnologies Company (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 78472W104 (CUSIP Number) November 3, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 13, 2020 |
EX-99.1 2 d72402dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT This joint filing agreement (this “Agreement”) is made and entered into as of November 13, 2020, by and among Temasek Holdings (Private) Limited, Fullerton Management Pte. Ltd., Temasek Life Sciences Private Limited, Elbrus Investments Pte. Ltd., and V-Sciences Investments Pte Ltd. The parties to this Agreement agree to prepare jo |
|
| November 4, 2020 |
Restated Certificate of Incorporation of SQZ Biotechnologies Company EX-3.1 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF SQZ BIOTECHNOLOGIES COMPANY The name of the corporation is SQZ Biotechnologies Company. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on March 22, 2013. This Restated Certificate of Incorporation of the corporation, which restates |
|
| November 4, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2020 SQZ BIOTECHNOLOGIES COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39662 46-2431115 (State or other jurisdiction of incorporation or |
|
| October 30, 2020 |
2020 Incentive Award Plan and form of agreements thereunder EX-99.2 Exhibit 99.2 SQZ BIOTECHNOLOGIES COMPANY 2020 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE |
|
| October 30, 2020 |
S-8 As filed with the Securities and Exchange Commission on October 30, 2020 Registration No. |
|
| October 30, 2020 |
2014 Stock Incentive Plan, as amended, and form of agreements thereunder EX-99.1 Exhibit 99.1 SQZ Biotechnologies Company 2014 Stock Incentive Plan 1. Purpose. The purpose of this plan (the “Plan”) is to secure for SQZ Biotechnologies Company., a Delaware corporation (the “Company”) and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Company and its parent and subsidiary cor |
|
| October 30, 2020 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-249422 PROSPECTUS 4,411,765 Shares Common Stock This is SQZ Biotechnologies Company’s initial public offering. We are offering 4,411,765 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price of our common stock is $16.00 per share. Our |
|
| October 30, 2020 |
EX-4.3 Exhibit 4.3 RESTATED CERTIFICATE OF INCORPORATION OF SQZ BIOTECHNOLOGIES COMPANY The name of the corporation is SQZ Biotechnologies Company. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on March 22, 2013. This Restated Certificate of Incorporation of the corporation, which restates |
|
| October 30, 2020 |
2020 Employee Stock Purchase Plan EX-99.3 Exhibit 99.3 SQZ BIOTECHNOLOGIES COMPANY 2020 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purposes of this SQZ Biotechnologies Company 2020 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the “Plan”) are to assist Eligible Employees of SQZ Biotechnologies Company, a Delaware corporation (the “Company”), and its Designated Subsidiaries in acquiring |
|
| October 27, 2020 |
CORRESP October 27, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christie Wong Lisa Vanjoske Chris Edwards Celeste Murphy Re: SQZ Biotechnologies Company Registration Statement on Form S-1 Registration No. 333-249422 Acceleration Request Requested Date: October 29, 2020 Requested Time: 4:00 PM, Eastern Daylig |
|
| October 27, 2020 |
CORRESP October 27, 2020 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| October 27, 2020 |
CORRESP October 27, 2020 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N. |
|
| October 26, 2020 |
Employment Agreement between the Registrant and Oliver Rosen, M.D., dated October 23, 2020 EX-10.13 15 d877186dex1013.htm EX-10.13 Exhibit 10.13 Employment Agreement This Employment Agreement (this “Agreement”), dated as of October 23, 2020, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the “Company”), and Oliver Rosen, M.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a |
|
| October 26, 2020 |
2014 Stock Incentive Plan, as amended, and form of agreements thereunder EX-10.1 Exhibit 10.1 SQZ Biotechnologies Company 2014 Stock Incentive Plan 1. Purpose. The purpose of this plan (the “Plan”) is to secure for SQZ Biotechnologies Company., a Delaware corporation (the “Company”) and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Company and its parent and subsidiary cor |
|
| October 26, 2020 |
2020 Employee Stock Purchase Plan EX-10.4 Exhibit 10.4 SQZ BIOTECHNOLOGIES COMPANY 2020 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purposes of this SQZ Biotechnologies Company 2020 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the “Plan”) are to assist Eligible Employees of SQZ Biotechnologies Company, a Delaware corporation (the “Company”), and its Designated Subsidiaries in acquiring |
|
| October 26, 2020 |
Amended and Restated Investors’ Rights Agreement, dated as of December 19, 2019, as amended EX-4.1 Exhibit 4.1 THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of December 19, 2019, by and among SQZ Biotechnologies Company, a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any Addi |
|
| October 26, 2020 |
Exhibit 3.3 RESTATED CERTIFICATE OF INCORPORATION OF SQZ BIOTECHNOLOGIES COMPANY The name of the corporation is SQZ Biotechnologies Company. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on March 22, 2013. This Restated Certificate of Incorporation of the corporation, which restates and in |
|
| October 26, 2020 |
2020 Incentive Award Plan and form of agreements thereunder EX-10.2 Exhibit 10.2 SQZ BIOTECHNOLOGIES COMPANY 2020 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE |
|
| October 26, 2020 |
Employment Agreement between the Registrant and Teri Loxam, dated October 23, 2020 EX-10.12 Exhibit 10.12 Employment Agreement This Employment Agreement (this “Agreement”), dated as of October 23, 2020, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the “Company”), and Teri Loxam (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if |
|
| October 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 SQZ Biotechnologies Company (Exact name of registrant as specified in its charter) Delaware 46-2431115 (State of incorporation or organization) (I.R.S. Employer Identification No.) 200 Arsenal Yard |
|
| October 26, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on October 26, 2020 Registration No. |
|
| October 26, 2020 |
Amended and Restated Bylaws of SQZ Biotechnologies Company EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF SQZ BIOTECHNOLOGIES COMPANY (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PR |
|
| October 26, 2020 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SQZ BIOTECHNOLOGIES COMPANY (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) SQZ Biotechnologies Company, a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. |
|
| October 26, 2020 |
Lease between the Registrant and Arsenal Yards Holding LLC, dated December 11, 2018 EX-10.6 13 d877186dex106.htm EX-10.6 Exhibit 10.6 LEASE From ARSENAL YARDS HOLDING LLC Landlord To SQZ BIOTECHNOLOGIES COMPANY Tenant Arsenal Yards, Watertown, Massachusetts TABLE OF CONTENTS Page ARTICLE 1: BASIC TERMS 1 ARTICLE 2: PREMISES; APPURTENANT RIGHTS; COMMON AREAS; PARKING; CHANGES TO DEVELOPMENT 4 2.01. Lease of Premises; Appurtenant Rights 4 2.01(a) General 4 2.01(b) Exclusions 4 2.01 |
|
| October 26, 2020 |
Form of Underwriting Agreement Exhibit 1.1 [●] SQZ Biotechnologies Company UNDERWRITING AGREEMENT [●], 2020 BOFA SECURITIES, INC. EVERCORE GROUP L.L.C. STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 c/o EVERCORE GROUP L.L.C. 55 East 52nd Street New York, New York 10055 c/o STIFEL, NICOLAUS & COMPANY, INCORPORATED 787 7th |
|
| October 26, 2020 |
Form of Indemnification Agreement for Directors and Officers EX-10.5 Exhibit 10.5 SQZ BIOTECHNOLOGIES COMPANY INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20[20] between SQZ Biotechnologies Company, a Delaware corporation (the “Company”), and [Name] (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers or in oth |
|
| October 26, 2020 |
Employment Agreement between the Registrant and Armon Sharei, Ph.D., dated October 23, 2020 EX-10.14 Exhibit 10.14 Employment Agreement This Employment Agreement (this “Agreement”), dated as of October 23, 2020, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the “Company”), and Armon Sharei, Ph.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effe |
|
| October 26, 2020 |
Non-Employee Director Compensation Program EX-10.3 Exhibit 10.3 SQZ BIOTECHNOLOGIES COMPANY NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of SQZ Biotechnologies Company (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or |
|
| October 14, 2020 |
October 14, 2020 FOIA CONFIDENTIAL TREATMENT REQUEST UNDER 17 C.F.R. §200.83 The entity requesting confidential treatment is: SQZ Biotechnologies Company 200 Arsenal Yards Blvd., Suite 210 Watertown, MA 02472 Certain confidential information in this letter has been omitted and provided separately to the Securities and Exchange Commission. Confidential treatment has been requested by SQZ Biotechnol |
|
| October 9, 2020 |
Warrant to Purchase Stock, dated October 21, 2015, issued to Silicon Valley Bank EX-4.3 Exhibit 4.3 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND |
|
| October 9, 2020 |
Subsidiaries of the Registrant EX-21.1 Exhibit 21.1 SUBSIDIARIES OF SQZ BIOTECHNOLOGIES COMPANY Legal Name of Subsidiary Jurisdiction of Organization SQZ Biotechnologies Security Corporation Massachusetts |
|
| October 9, 2020 |
Bylaws of the Registrant (currently in effect) EX-3.2 Exhibit 3.2 BY-LAWS OF SQZ BIOTECHNOLOGIES COMPANY Section 1 CERTIFICATE OF INCORPORATION AND BY-LAWS 1.1 These by-laws are subject to the certificate of incorporation of the corporation. In these by-laws, references to the certificate of incorporation and by-laws mean the provisions of the certificate of incorporation and the by-laws as are from time to time in effect. Section 2 OFFICES 2. |
|
| October 9, 2020 |
2014 Stock Incentive Plan, as amended, and form of agreements thereunder Exhibit 10.1 SQZ Biotechnologies Company 2014 Stock Incentive Plan 1. Purpose. The purpose of this plan (the “Plan”) is to secure for SQZ Biotechnologies Company., a Delaware corporation (the “Company”) and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Company and its parent and subsidiary corporation |
|
| October 9, 2020 |
EX-10.9 Exhibit 10.9 Last Modified: Dec. 1, 2015 TLO: TI’/BR/SN SQZ BIOTECHNOLOGIES, INC. MASSACHUSETTS INSTITUTE OF TECHNOLOGY AMENDED AND RESTATED EXCLUSIVE PATENT LICENSE AGREEMENT [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicl |
|
| October 9, 2020 |
Amended and Restated Investors’ Rights Agreement, dated as of December 19, 2019 EX-4.1 4 d877186dex41.htm EX-4.1 Exhibit 4.1 THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of December 19, 2019, by and among SQZ Biotechnologies Company, a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as |
|
| October 9, 2020 |
Specimen Common Stock Certificate EX-4.2 Exhibit 4.2 COMMON STOCK SHARES CUSIP SEE REVERSE FOR CERTAIN DEFINITIONS SQZ Biotechnologies Company INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT SPECIMEN IS THE RECORD HOLDER OF FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF SQZ Biotechnologies Company transferable on the books of the Corporation in person or by duly author |
|
| October 9, 2020 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SQZ BIOTECHNOLOGIES COMPANY (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) SQZ Biotechnologies Company, a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERT |
|
| October 9, 2020 |
EX-10.7 8 d877186dex107.htm EX-10.7 Exhibit 10.7 Confidential License and Collaboration Agreement This Agreement is entered into with effect as of the Effective Date (as defined below) by and between F.Hoffmann-La Roche Ltd with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) and Hoffmann-La Roche Inc. with an office and place of business at 150 Cl |
|
| October 9, 2020 |
Offer Letter between the Registrant and Oliver Rosen, M.D., dated October 31, 2018 Exhibit 10.11 SQZ Biotechnologies Company 134 Coolidge Avenue Watertown, Massachusetts 02472 October 31, 2018 Oliver Rosen Dear Oliver: SQZ Biotechnologies Company (the “Company”) is pleased to offer you the position of Chief Medical Officer in Watertown, MA. The following represents our offer of employment to join the Company and is contingent upon satisfactory completion of the Company’s standar |
|
| October 9, 2020 |
Offer Letter between the Registrant and Teri Loxam, dated July 17, 2019 EX-10.10 Exhibit 10.10 SQZ Biotechnologies Company 134 Coolidge Avenue Watertown, Massachusetts 02472 July 17, 2019 Teri Loxam Dear Teri: SQZ Biotechnologies Company (the “Company”) is pleased to offer you the position of Chief Financial Officer in Watertown, MA. The following represents our offer of employment to join the Company and is contingent upon satisfactory completion of your references a |
|
| October 9, 2020 |
EX-10.8 Exhibit 10.8 Accord relating to License and Collaboration Agreement This accord (“Accord”) effective November 5, 2019 (“Accord Effective Date”) is made in connection with the License and Collaboration Agreement effective October 5, 2018 by and between F. Hoffmann-La Roche Ltd (“Roche Basel”) and Hoffmann-La Roche Inc. (“"Roche US”; Roche Basel and Roche US together referred to as “Roche”), |
|
| October 9, 2020 |
Letter of Katz, Nannis + Solomon, P.C., Independent Public Accountants EX-16.1 Exhibit 16.1 October 9, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by SQZ Biotechnologies Company pursuant to Item 304(a)(1) of Regulation S-K (copy attached), which we understand will be filed with the Securities and Exchange Commission as part of the Registration Statement on Form S-1 of SQZ Biotechnolog |
|
| October 9, 2020 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on October 9, 2020 Registration No. |
|
| September 25, 2020 |
DRS/A Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 24, 2020 as Amendment No. |
|
| September 24, 2020 |
DRSLTR 200 Clarendon Street Boston, Massachusetts 02116 Tel: +1.617.948.6000 Fax: +1.617.948.6001 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh Düsseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Hotiuston Silicon Valley London Singapore September 24, 2020 Los Angeles Tokyo Madrid W |
|
| August 28, 2020 |
EX-10.9 4 filename4.htm Exhibit 10.9 Last Modified: Dec. 1, 2015 TLO: TI’/BR/SN SQZ BIOTECHNOLOGIES, INC. MASSACHUSETTS INSTITUTE OF TECHNOLOGY AMENDED AND RESTATED EXCLUSIVE PATENT LICENSE AGREEMENT [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the regis |
|
| August 28, 2020 |
Accord relating to License and Collaboration Agreement EX-10.8 Exhibit 10.8 Accord relating to License and Collaboration Agreement This accord (“Accord”) effective November 5, 2019 (“Accord Effective Date”) is made in connection with the License and Collaboration Agreement effective October 5, 2018 by and between F. Hoffmann-La Roche Ltd (“Roche Basel”) and Hoffmann-La Roche Inc. (“"Roche US”; Roche Basel and Roche US together referred to as “Roche”), |
|
| August 28, 2020 |
License and Collaboration Agreement EX-10.7 Exhibit 10.7 Confidential License and Collaboration Agreement This Agreement is entered into with effect as of the Effective Date (as defined below) by and between F.Hoffmann-La Roche Ltd with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) and Hoffmann-La Roche Inc. with an office and place of business at 150 Clove Road, Suite 8, Little Fa |
|
| August 28, 2020 |
DRS/A Table of Contents As confidentially submitted to the Securities and Exchange Commission on August 27, 2020 as Amendment No. |
|
| August 27, 2020 |
200 Clarendon Street Boston, Massachusetts 02116 Tel: +1.617.948.6000 Fax: +1.617.948.6001 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh Düsseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore August 27, 2020 Los Angeles Tokyo Madrid Washington, D |
|
| July 21, 2020 |
BY-LAWS SQZ BIOTECHNOLOGIES COMPANY EX-3.2 Exhibit 3.2 BY-LAWS OF SQZ BIOTECHNOLOGIES COMPANY Section 1 CERTIFICATE OF INCORPORATION AND BY-LAWS 1.1 These by-laws are subject to the certificate of incorporation of the corporation. In these by-laws, references to the certificate of incorporation and by-laws mean the provisions of the certificate of incorporation and the by-laws as are from time to time in effect. Section 2 OFFICES 2. |
|
| July 21, 2020 |
EX-3.1 2 filename2.htm Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SQZ BIOTECHNOLOGIES COMPANY (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) SQZ Biotechnologies Company, a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), |
|
| July 21, 2020 |
DRS Table of Contents As confidentially submitted to the Securities and Exchange Commission on July 20, 2020 Registration No. |
|
| July 21, 2020 |
SQZ Biotechnologies Company 2014 Stock Incentive Plan EX-10.1 Exhibit 10.1 SQZ Biotechnologies Company 2014 Stock Incentive Plan 1. Purpose. The purpose of this plan (the “Plan”) is to secure for SQZ Biotechnologies Company., a Delaware corporation (the “Company”) and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Company and its parent and subsidiary cor |
|
| July 21, 2020 |
EX-21.1 Exhibit 21.1 SUBSIDIARIES OF SQZ BIOTECHNOLOGIES COMPANY Legal Name of Subsidiary Jurisdiction of Organization SQZ Biotechnologies Security Corporation Massachusetts |
